Doripenem Injectable (Iv) 500 mg, 1 g per vial Suppliers & Bulk Manufacturers

Available Forms: Injectable (IV)

Available Strengths: 500 mg, 1 g per vial

Reference Brands: Doribax(US & EU)

Category: Antibiotics

Doripenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, causing bacterial lysis and death. It offers broad-spectrum activity against resistant gram-negative bacteria, including Pseudomonas. Benefits include rapid, effective bacterial eradication, high tissue penetration, and once-daily dosing, making it ideal for severe, hospital-based infections.

Product Description: Doripenem injectable is approved in the EU and US for severe bacterial infections such as pneumonia, intra-abdominal, and urinary tract infections. In the EU, brands like Doribax are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA approval relies on extensive clinical data; generic formulations are available. Both regions require detailed dossiers, including clinical trial results, manufacturing practices, and pharmacovigilance plans for approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We facilitate seamless market access, ensuring adherence to European and US standards for safe, effective antimicrobial therapy.